Granulosa cell tumors express erbB4 and are sensitive to the cytotoxic action of heregulin-β2/PE40

Cancer Research

Volumn 58, Issue 9, 1998, Pages 1773-1778

  Furger, Christophe ^a   Fiddes, Rodney J ^a   Quinn, David I ^a   Bova, Ron J ^a   Daly, Roger J ^a   Sutherland, Robert L ^a  

^a ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; FOLLITROPIN; LIGAND; NEU DIFFERENTIATION FACTOR;

ARTICLE; GENE AMPLIFICATION; GENE OVEREXPRESSION; GRANULOSA CELL TUMOR; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LIGAND BINDING; MITOGENESIS; MOLECULAR GENETICS; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; PROTEIN PHOSPHORYLATION; TUMOR CELL LINE;

BLOTTING, NORTHERN; BLOTTING, WESTERN; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; CARRIER PROTEINS; CELL DIVISION; CELL SURVIVAL; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; GLYCOPROTEINS; GRANULOSA CELL TUMOR; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOHISTOCHEMISTRY; LIGANDS; NEUREGULIN-1; OVARIAN NEOPLASMS; PHOSPHORYLATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 0032080806     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Newland, E. S., and Paradinas, F. J. Ovarian germ-cell and other rare ovarian tumours. In: M. Peckham, H. Pinedo, and U. Veronesi (eds.), Oxford Textbook of Oncology, Vol. 2, pp. 1308-1324. Oxford, United Kingdom: Oxford University Press, 1995.
2. Fox, H. Sex cord-stromal tumours of the ovary. J. Pathol., 145: 127-148, 1985.
3. Pelletier, J., Bruening, W., Kashtan, C. E., Mauer, S. M., Manivel, J. C., Striegel, J. E., Houghton, D. C., Junien, C., Habib, R., Fouser, L., Fine, R. N., Silverman, B. L., Haber, D. A., and Housman, D. Germline mutations in the Wilms' tumor suppressor gene are associated with abnormal urogenital development in Denys-Drash syndrome. Cell, 67: 437-447, 1991.
4. Coppes, M. J., Ye, Y., Rackley, R., Zhao, X. L., Liefere, G. J., Casey, G., and Williams, B. R. Analysis of WT1 in granulosa cell and other sex cord-stromal tumors. Cancer Res., 53: 2712-2714, 1993.
5. Kappes, S., Milde-Langosch, K., Kressin, P., Passlack, B., Dockhorn-Dwomiczak, B., Rohlke, P., and Loning, T. p53 mutations in ovarian tumors, detected by temperature-gradient gel electrophoresis, direct sequencing and immunohistochemistry. Int. J. Cancer, 64: 52-59, 1995.
6. Kotlar, T. J., Young, R. H., Albanese, C., Crowley, W. F., Jr., Scully, R. E., and Jameson, J. L. A mutation in the follicle-stimulating hormone receptor occurs frequently in human ovarian sex cord tumors. J. Clin. Endocrinol. Metab., 82: 1020-1026, 1997.
7. Tennent, B. J., Beamer, W. G., Shultz, L. D., and Adamson, E. D. Epidermal growth factor receptors in spontaneous ovarian granulosa cell tumors of SWR-derived mice. Int. J. Cancer, 44: 477-482, 1989.
8. Berchuck, A., Kamel, A., Whitaker, R., Kerns, B., Olt, G., Kinney, R.,Soper, J. T., Dodge, R., Clarke-Pearson, D. L., Marks, P., McKenzie, S., Yin, S., and Bast, R. C., Jr.. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res., 50: 4087-4091, 1990.
9. Kraus, M. H., Issing, W., Miki, T., Popescu, N. C., and Aaronson, S. A. Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family evidence for overexpression in a subset of human mammary tumors. Proc. Natl Acad. Sci. USA, 86: 9193-9197, 1989.
10. Plowman, G. D., Culouscou, J. M., Whitney, G. S., Green, J. M., Carlton, G. W., Foy, L., Neubauer, M. G., and Shoyab, M. Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family. Proc. Natl Acad. Sci. USA, 90: 1746-1750, 1993.
11. Fiddes, R. J., Janes, P. W., Sanderson, G. M., Sivertsen, S. P., Sutherland, R. L., and Daly, R. J. Heregulin (HRG)-induced mitogenic signaling and cytotoxic activity of a HRG/PE40 ligand toxin in human breast cancer cells. Cell Growth Differ., 6: 1567-1577, 1995.
12. Cobb, M. H., and Goldsmith, E. J. How MAP kinases are regulated. J. Biol. Chem., 270: 14843-14846, 1995.
13. van den Berg-Bakker, C. A., Hagemeijer, A., Franken-Postma, E. M., Smit, V. T., Kuppen, P. J., van Ravenswaay Claasen, H. H., Cornelisse, C. J., and Schrier, P. I. Establishment and characterization of 7 ovarian carcinoma cell lines and one granulosa tumor cell line: growth features and cytogenetics. Int. J. Cancer, 53: 613-620, 1993.
14. Siegall, C. B., Bacus, S. S., Cohen, B. D., Plowman, G. D., Mixan, B., Chace, D., Chin, D. M., Goetze, A., Green, J. M., Hellstrom, I., Hellstrom, K. E., and Perry Fell, H. HER4 expression correlates with cytotoxicity directed by a heregulin-toxin fusion protein. J. Biol. Chem., 270: 7625-7630, 1995.
15. Kihara, A., and Pastan, I. Cytotoxic activity of chimeric toxins containing the epidermal growth factor-like domain of heregulins fused to PE38KDEL, a truncated recombinant form of Pseudomonas exotoxin. Cancer Res., 55: 71-77, 1995.
16. Fiddes, R. J., Janes, P. W., Sivertsen, S. P., Sutherland, R. L., Musgrove, E. A., and Daly, R. J. Inhibition of the MAP kinase cascade blocks heregulin-induced cell cycle progression in T-47D breast cancer cells. Oncogene, in press, 1998.
17. Haugen, D. R., Akslen, L. A., Varhaug, J. E., and Lillehaug, J. R. Expression of c-erbB-3 and c-erbB-4 proteins in papillary thyroid carcinomas. Cancer Res., 56: 1184-1188, 1996.
18. Gilbertson, R. J., Perry, R. H., Kelly, P. J., Pearson, A. D., and Lunec, J. Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. Cancer Res., 57: 3272-3280, 1997.
19. Vartanian, T., Goodearl, A., Viehover, A., and Fischbach, G. Axonal neuregulin signals cells of the oligodendrocyte lineage through activation of HER4 and Schwann cells through HER2 and HER3. J. Cell Biol., 137: 211-220, 1997.
20. Elenius, K., Corfas, G., Paul, S., Choi, C. J., Rio, C., Plowman, G. D., and Klagsbrun, M. A novel juxtamembrane domain isoform of HER4/ErbB4. Isoform-specific tissue distribution and differential processing in response to phorbol ester. J. Biol. Chem., 272: 26761-26768, 1997.
21. Beerli, R. R., Graus-Porta, D., Woods-Cook, K., Chen, X., Yarden, Y., and Hynes, N. E. Neu differentiation factor activation of ErbB-3 and ErbB-4 is cell specific and displays a differential requirement for ErbB-2. Mol. Cell. Biol., 15: 6496-6505, 1995.
22. Lewis, G. D., Lofgren, J. A., McMurtrey, A. E., Nuijens, A., Fendly, B. M., Bauer, K. D., and Sliwkowski, M. X. Growth regulation of human breast and ovarian tumor cells by heregulin: evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness. Cancer Res., 56: 1457-1465, 1996.
23. Juhl, H., Downing, S. G., Wellstein, A., and Czubayko, F. HER-2/neu is rate-limiting for ovarian cancer growth. Conditional depletion of her-2/neu by ribozyme targeting. J. Biol. Chem., 272: 29482-29486, 1997.
24. Simpson, B. J., Phillips, H. A., Lessells, A. M., Langdon, S. P., and Miller, W. R. c-erbB growth-factor-receptor proteins in ovarian tumours. Int. J. Cancer, 64: 202-206, 1995.
25. Prigent, S. A., Lemoine, N. R., Hughes, C. M., Plowman, G. D., Selden, C., and Gullick, W. J. Expression of the c-erbB-3 protein in normal human adult and fetal tissues. Oncogene, 7: 1273-1278, 1992.